<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361217</url>
  </required_header>
  <id_info>
    <org_study_id>39288</org_study_id>
    <secondary_id>P01GM032165</secondary_id>
    <nct_id>NCT01361217</nct_id>
  </id_info>
  <brief_title>The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity</brief_title>
  <acronym>FLUOXETINE</acronym>
  <official_title>The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inhibitory drug-drug interactions (DDIs) are a considerable concern as inhibition of drug's
      clearance can lead to increased plasma concentrations and subsequent adverse events and
      toxicities. Fluoxetine (ProzacÂ®) is a widely prescribed antidepressant, but is also a potent
      inhibitor of cytochrome P450 (CYP) enzymes. Fluoxetine was chosen as the model inhibitor for
      this study because it is a clinically important inhibitor of multiple CYP enzymes with
      varying potencies for each isoform. From in vitro data, fluoxetine is predicted to be a
      moderate inhibitor of CYP2D6, but a strong inhibitor of CYP2C19 and CYP3A4. However, in vivo
      fluoxetine causes a potent interaction with CYP2D6 and a weak-to-no interaction with CYP3A4.
      The magnitude of the in vivo interaction of fluoxetine with CYP2C19 is not known. This in
      vitro-to-in vivo discrepancy is of concern for two reasons: 1) In clinical drug development,
      in vivo drug-drug interactions are tested only when in vitro experiments predict a risk for
      in vivo DDIs and 2) Because in vivo DDI's are tested using a rank order approach of going
      from the most potent in vitro interaction to the least potent until no interaction in vivo is
      observed. In this study the interaction between fluoxetine and CYP3A4, CYP2C19 and CYP2D6
      will be quantified simultaneously and the quantitative in vitro-to-in vivo predictions
      tested. Fluoxetine will be orally administered daily for 14 days and CYP1A2, CYP3A4, CYP2C19
      and CYP2D6 activity will be tested in the end of fluoxetine dosing using a cocktail of CYP
      probes including caffeine, midazolam, omeprazole and dextromethorphan. Lovastatin will be
      administered on a separate day and used as a second CYP3A4 probe to test whether CYP3A4
      inhibition by fluoxetine depends on the contribution of intestinal CYP3A4 to the probe
      clearance. Plasma and urine samples will be collected for 12 and 24 hrs, respectively, during
      the control sessions (before fluoxetine administration) and for 24 hrs during the treatment
      sessions (fluoxetine multiple dose). The concentrations of each of the probe drugs and their
      metabolites (when applicable) as well as fluoxetine and its metabolites will be measured in
      the collected samples and pharmacokinetic analysis will be performed. The primary outcome
      measures for CYP inhibition will be the increase in the area under plasma concentrations time
      curve (AUC) of each of the probes.The null hypothesis of this study is that the area under
      plasma concentrations time curves (AUCs) of caffeine, dextromethorphan, omeprazole, midazolam
      or lovastatin are the same between the control session and the fluoxetine session. Because
      lovastatin has the greatest variability in its baseline pharmacokinetics the study was
      powered based on the specific null hypothesis for lovastatin. The alternative hypothesis is
      that fluoxetine decreases the clearance of the probe drugs resulting in a significant
      increase in the AUCs between the control and study sessions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lovastatin AUC in the Presence of Fluoxetine</measure>
    <time_frame>The primary outcome will be assessed within 2 months after the last subject is enrolled or at 2 years from the start of study enrollment, which ever is sooner.</time_frame>
    <description>Our primary outcome measure will be the interaction of fluoxetine with CYP3A4. A 50% increase in the AUC for lovastatin plus hydroxy-lovastatin acid (the active form of lovastatin) between treatment day 14 (study day 20) and control days (study day 2) is considered clinically significant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of Dextromethorphan, Midazolam and Omeprazole in the Presence of Fluoxetine</measure>
    <time_frame>The secondary outcome will be assessed within 2 months after the last subject is enrolled or at 2 years from the start of study enrollment, which ever is sooner.</time_frame>
    <description>Our secondary outcome measure will be the interaction between fluoxetine and each CYP evaluated in the cocktail. A 50% increase in the AUC of caffeine (CYP1A2), dextromethorphan (CYP2D6), omeprazole (CYP2C19) or midazolam (CYP3A4) between treatment and control days is considered clinically significant. The interaction of fluoxetine with caffeine (CYP1A2) will be considered as a negative control for the study. These AUCs will be measured on study day 1 (control day) and study day 18</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Drug-Drug Interaction</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Fluoxetine DDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Only arm in the study. Successive Control (Study Days 1 and 3) and fluoxetine multiple-dose treatment (Study Days 16 and 18) Sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan</intervention_name>
    <description>1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.
On study day 1 and study day 18, 100mg caffeine, 2mg midazolam, 30mg dextromethorphan and 20mg omeprazole (enteric coated formulation) orally with 250mL of water.
On study day 3 and study day 20 20mg of lovastatin with 250mL of water.</description>
    <arm_group_label>Fluoxetine DDI</arm_group_label>
    <other_name>Prozac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be 18-50 years old.

          -  Subjects must be currently in good health with normal gastrointestinal and heart
             function (as determined by medical history)

          -  Laboratory values indicating normal liver (Serum Albumin 3.9 - 5.0 g/dL, Total
             Bilirubin &lt; 1.4mg/dL, Alanine Transaminase 9 - 60 IU/L and Aspartate Transaminase 10 -
             40 IU/L) and kidney (Serum Creatinine &lt; 1.5 mg/dL and Blood Urea Nitrogen 7 - 20
             mg/dL) function as well as normal blood glucose values (Fasting Blood Glucose &lt; 100
             mg/dL).

          -  Subjects must have no known allergies to fluoxetine or other selective serotonin
             reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), benzodiazepine
             drugs, caffeine, omeprazole, dextromethorphan, lovastatin or any chemically related
             drug.

          -  Women of childbearing age must be willing to use measures to avoid conception during
             the study period and willing to have a pregnancy test on Study Days 1 and 16.

          -  Subjects must agree not to take any known substrates, inhibitors, inducers or
             activators of cytochrome P450 (CYP) CYP1A2, CYP3A4, CYP2C19 and CYP2D6 for two weeks
             before the start of each study through three weeks after the last day of study. This
             list includes but is not restricted to antidepressant and antipsychotic agents, azole
             antifungal agents, macrolide antibiotics, anti-epileptic medications, antihypertensive
             agents and cholesterol lowering agents. They must also be willing to avoid ingesting
             grapefruit, grapefruit juice or other grapefruit containing products, and any
             herbal-based nutrient supplement or medication for the same period of time. Use of
             oral contraceptives will be permitted.

          -  Subjects must be willing to avoid caffeine-containing foods, beverages, or dietary
             supplements for 24 hrs prior to and throughout each study session and avoid alcohol
             for 48 hrs prior to and throughout each study session.

          -  Subjects must be willing to avoid heavy exercise during the study

        Exclusion Criteria:

          -  Current cigarette smoker

          -  History of liver, kidney, gastrointestinal or heart disease

          -  Lab test results indicative of abnormal liver or kidney function, or diabetes (see
             above inclusion criteria).

          -  Allergy to any monoamine oxidase inhibitors (MAOIs) or any other chemically related
             drug or to benzodiazepine drug

          -  Prior experience of side effects to fluoxetine or other selective serotonin reuptake
             inhibitors (SSRIs)

          -  CYP2D6 or CYP2C19 poor metabolizer genotype or CYP3A5 expressor genotype

          -  Recent ingestion (&lt; 2 weeks) of any medication known to be metabolized by or alter
             CYP1A2, CYP3A4, CYP2C19 or CYP2D6 activity

          -  A positive pregnancy test or breastfeeding

          -  History of diabetes, peptic ulcer or inflammatory bowel disease

          -  Overweight; a body mass index â¥ 30 or underweight; a body mass index of â¤ 18

          -  Use of chronic prescription or over-the-counter medications (except oral
             contraceptives)

          -  Use of antidepressants during the last two weeks preceding the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Isoherranen, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington, School of Pharmacy, Department of Pharmaceutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Connie Davis, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington, Department of Medicine</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2011</study_first_posted>
  <results_first_submitted>December 9, 2013</results_first_submitted>
  <results_first_submitted_qc>June 25, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2018</results_first_posted>
  <last_update_submitted>June 25, 2018</last_update_submitted>
  <last_update_submitted_qc>June 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Nina Isoherranen</investigator_full_name>
    <investigator_title>Professor, PHARM: Department of Pharmaceutics</investigator_title>
  </responsible_party>
  <keyword>Fluoxetine</keyword>
  <keyword>CYP3A4</keyword>
  <keyword>CYP2D6</keyword>
  <keyword>CYP2C19</keyword>
  <keyword>Drug-Drug Interaction</keyword>
  <keyword>Multi-CYP Inhibition</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluoxetine DDI</title>
          <description>Only arm in the study. Successive Control (Study Days 1 and 3) and fluoxetine multiple-dose treatment (Study Days 16 and 18) Sessions.
Fluoxetine: 1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluoxetine DDI</title>
          <description>Only arm in the study. Successive Control (Study Days 1 and 3) and fluoxetine multiple-dose treatment (Study Days 16 and 18) Sessions.
Fluoxetine: 1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>chicano</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lovastatin AUC in the Presence of Fluoxetine</title>
        <description>Our primary outcome measure will be the interaction of fluoxetine with CYP3A4. A 50% increase in the AUC for lovastatin plus hydroxy-lovastatin acid (the active form of lovastatin) between treatment day 14 (study day 20) and control days (study day 2) is considered clinically significant.</description>
        <time_frame>The primary outcome will be assessed within 2 months after the last subject is enrolled or at 2 years from the start of study enrollment, which ever is sooner.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lovastatin AUC After Fluoxetine Dosing</title>
            <description>Only arm in the study. Successive Control (Study Days 1 and 3) and fluoxetine multiple-dose treatment (Study Days 16 and 18) Sessions.
Fluoxetine: 1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.</description>
          </group>
          <group group_id="O2">
            <title>Lovastatin Before Fluoxetine</title>
            <description>control</description>
          </group>
        </group_list>
        <measure>
          <title>Lovastatin AUC in the Presence of Fluoxetine</title>
          <description>Our primary outcome measure will be the interaction of fluoxetine with CYP3A4. A 50% increase in the AUC for lovastatin plus hydroxy-lovastatin acid (the active form of lovastatin) between treatment day 14 (study day 20) and control days (study day 2) is considered clinically significant.</description>
          <units>nmol*hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170" spread="70"/>
                    <measurement group_id="O2" value="180" spread="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of Dextromethorphan, Midazolam and Omeprazole in the Presence of Fluoxetine</title>
        <description>Our secondary outcome measure will be the interaction between fluoxetine and each CYP evaluated in the cocktail. A 50% increase in the AUC of caffeine (CYP1A2), dextromethorphan (CYP2D6), omeprazole (CYP2C19) or midazolam (CYP3A4) between treatment and control days is considered clinically significant. The interaction of fluoxetine with caffeine (CYP1A2) will be considered as a negative control for the study. These AUCs will be measured on study day 1 (control day) and study day 18</description>
        <time_frame>The secondary outcome will be assessed within 2 months after the last subject is enrolled or at 2 years from the start of study enrollment, which ever is sooner.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Midazolam, Caffeine, Omeprazole, Caffeine AUC After Fluoxetine</title>
            <description>Only arm in the study. Successive Control (Study Days 1 and 3) and fluoxetine multiple-dose treatment (Study Days 16 and 18) Sessions.
Fluoxetine: 1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Dextromethorphan, Midazolam and Omeprazole in the Presence of Fluoxetine</title>
          <description>Our secondary outcome measure will be the interaction between fluoxetine and each CYP evaluated in the cocktail. A 50% increase in the AUC of caffeine (CYP1A2), dextromethorphan (CYP2D6), omeprazole (CYP2C19) or midazolam (CYP3A4) between treatment and control days is considered clinically significant. The interaction of fluoxetine with caffeine (CYP1A2) will be considered as a negative control for the study. These AUCs will be measured on study day 1 (control day) and study day 18</description>
          <units>nmol*hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>caffeine control AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43000" spread="22000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine treatment AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43000" spread="15000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dextromethophan control AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" spread="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dextromethorphan treatment AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1850" spread="800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Omeprazole control AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1200" spread="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>omeprazole treatment AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8500" spread="3600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>midazolam control AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>midazolam treatment AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fluoxetine DDI</title>
          <description>Only arm in the study. Successive Control (Study Days 1 and 3) and fluoxetine multiple-dose treatment (Study Days 16 and 18) Sessions.
Fluoxetine: 1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <description>One subject experienced an anxiety attack during the study. No other adverse events reported.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nina Isoherranen</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-5432517</phone>
      <email>ni2@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

